New Zealand Expands ADHD Stimulant Prescribing Powers to Boost Access
New Zealand has updated its prescribing regulations for Attention-Deficit/Hyperactivity Disorder (ADHD) stimulant medications. These significant changes, effective February 1, 2026, are designed to broaden the scope of healthcare professionals authorized to assess, diagnose, and initiate treatment. The aim is to enhance access and expedite care for individuals with ADHD across the country.
Overview of Regulatory Changes
Associate Health Minister Matt Doocey announced the changes, stating they are designed to provide faster support for New Zealanders with ADHD. Medsafe and Pharmac have implemented new rules to widen prescribing capabilities for ADHD medications.
"These changes are designed to provide faster support for New Zealanders with ADHD."
Previously, general practitioners (GPs) and nurse practitioners were limited to prescribing ADHD medicines only after receiving a written recommendation from a paediatrician or psychiatrist, or for patients who had already been diagnosed and received their initial prescription.
Expanded Scope for Diagnosis and Treatment
Under the revised regulations, the scope for diagnosis and treatment has been significantly expanded:
- Adults (18 years and older): Vocationally registered specialist GPs and nurse practitioners, operating within their practice area, are now authorized to diagnose ADHD and initiate stimulant medication treatment.
- Children and Teens (under 18 years): While specialist services will continue to handle assessments, nurse practitioners working within paediatric or child and adolescent mental health teams can now diagnose ADHD and initiate treatment.
The government acknowledges that many GPs and nurse practitioners already possess the necessary skills for ADHD management, often working in conjunction with psychiatrists.
Implementation and Access Considerations
Dr. Jin Russell, Chief Clinical Advisor Child and Youth, advised that individuals seeking an ADHD assessment should continue to contact their general practice first to determine available local services. Dr. Russell noted that these changes aim to develop the specialist workforce and pathways for assessments.
It was also stated that these services may not be immediately available nationwide, and not all GPs may adopt this practice, but the new rules create additional pathways for ADHD treatment.
ADHD assessments are described as complex and time-consuming, typically requiring one to two hours and potentially spanning multiple appointments. The cost of such assessments is subject to the service type, local funding, and time dedicated to assessment and follow-up.
Funded Medications and Supply Management
The new rules enable eligible GPs and nurse practitioners to prescribe publicly funded stimulant medications for ADHD, including methylphenidate, dexamfetamine, and lisdexamfetamine.
Pharmac is currently managing the supply of ADHD stimulant medicines and investigating alternative brands and treatments. Ongoing global shortages are attributed to high demand and limited manufacturing capacity.
Broader Initiatives to Improve Access
The expansion of diagnostic and treatment access is part of a series of measures designed to improve access to ADHD medicines. These broader initiatives include:
- Special Authorities: Pharmac has removed the two-year renewal requirement for special authorities, which enable funded access to stimulant medications.
- New Medicine Funding: Pharmac has also provided funding for a new ADHD medicine.
The government acknowledges that untreated ADHD can significantly affect education, employment, relationships, and overall mental health, and aims to connect individuals with appropriate support earlier.
Effective Date
The updated prescribing regulations outlined in these changes are effective as of February 1, 2026.